Form 4: Vertex Executive Gains Shares from Performance Awards

Vertex Pharmaceuticals' EVP, Chief Technical Operations Officer, Edward Morrow Atkinson III, acquired 7,817 shares of common stock through performance-based awards.

Summary

• Edward Morrow Atkinson III, Executive Vice President, Chief Technical Operations Officer of Vertex Pharmaceuticals Inc. (VRTX), reported the acquisition of common stock.
• On January 22, 2026, Mr. Atkinson acquired 3,934 shares of common stock at a price of $0 per share.
• These 3,934 shares represent earned performance shares from a performance stock unit (PSU) award granted on February 1, 2023, with performance-vesting requirements certified on January 22, 2026, and scheduled to vest on February 13, 2026.
• Additionally, on January 22, 2026, Mr. Atkinson acquired another 3,883 shares of common stock at a price of $0 per share.
• These 3,883 shares are also earned performance shares from a PSU award granted on February 12, 2025, with performance-vesting requirements certified on January 22, 2026, and scheduled to vest in installments beginning February 24, 2026.
• Following these transactions, Mr. Atkinson beneficially owns a total of 24,669 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The filing indicates successful achievement of performance goals by a key executive, leading to an increase in their equity stake. This is a positive signal regarding executive performance and alignment with company objectives, though it is a routine compensation event.

Positives

• The executive successfully met performance goals associated with two separate performance stock unit awards.
• The acquisition of shares at a $0 price indicates the successful vesting of incentive compensation, aligning executive interests with shareholder value creation.
• An increase in the executive's beneficial ownership demonstrates continued commitment to the company's long-term success.

Future Outlook

The acquired shares from the first performance stock unit award are scheduled to vest on February 13, 2026, while the shares from the second award will vest in installments beginning February 24, 2026.

Industry Context

The acquisition of shares through performance-based stock unit awards is a standard practice in the biotechnology and pharmaceutical industry for executive compensation, designed to incentivize long-term performance and align management interests with shareholder returns.

Comparison to Industry Standards

• Performance-based equity compensation, such as the performance stock unit awards detailed, is a common and widely accepted practice across the S&P 500 and particularly within the high-growth biotech sector, including peers like Regeneron Pharmaceuticals (REGN) and Amgen (AMGN).
• The structure of these awards, where shares are earned upon the achievement of specific performance goals and then vest over time, is consistent with best practices in corporate governance to ensure executives are rewarded for tangible results.
• The $0 acquisition price is typical for earned performance shares, reflecting that the value was earned through performance rather than purchased at market price, similar to how restricted stock units (RSUs) are often granted and vest.

Stakeholder Impact

• Shareholders: The vesting of performance shares is a planned component of executive compensation, which can lead to minor dilution but is generally viewed as a cost of incentivizing strong management performance.
• Employees: The successful vesting of executive performance awards can serve as a positive example of the company's commitment to rewarding achievement of strategic goals.
• Executive (Edward Morrow Atkinson III): Directly benefits from increased equity ownership, enhancing personal wealth and aligning financial interests with the company's stock performance.

Next Steps

• The 3,934 shares from the 02/01/2023 PSU award will vest on February 13, 2026.
• The 3,883 shares from the 02/12/2025 PSU award will vest in installments beginning February 24, 2026.

Key Dates

Keywords

VRTX, Vertex Pharmaceuticals, Form 4, Insider Transaction, Performance Shares, Executive Compensation, Stock Award, Equity Compensation